Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3
TEL AVIV, Israel and SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from the company's Phase 2 SPRING trial of nebokitug (CM-101) in primary sclerosing cholangitis (PSC)1 was presented in an oral Distinguished Abstract Plenary session at Digestive Disease Week® (DDW 2025) in San Diego, California.
Paul J. Pockros, MD, Director, Liver Disease Center Scripps Clinic and Director of SC Liver Research Consortium, who was a SPRING trial investigator, presented the nebokitug data. He noted, 'PSC is a potentially devastating progressive disease that lacks any FDA-approved therapies. The data from the SPRING trial are very encouraging, showing that nebokitug appears safe and well-tolerated over 48 weeks of treatment. Notably, patients with more active moderate to severe disease showed sustained improvements in multiple biomarkers associated with disease progression. We believe these findings suggest that nebokitug may have disease-modifying potential and support developing nebokitug 20 mg/kg in a Phase 3 clinical study in patients with PSC.'
The DDW 2025 session presented data from the double-blind, placebo-controlled 15-week treatment period showing that nebokitug was well-tolerated and had a safety profile comparable to placebo. Nebokitug demonstrated dose dependent anti-inflammatory, anti-fibrotic and anti-cholestatic effects in patients with PSC. In a prespecified subgroup of patients with moderate to advanced disease, patients treated with nebokitug showed broad and consistent improvement in biomarkers that have been associated with better clinical outcomes.
The presentation also included data from the open label extension portion of the study, in which all eligible study patients received nebokitug for up to an additional 33 weeks. This data showed that nebokitug was safe and well-tolerated for up to 48 weeks of treatment. Patients treated with nebokitug showed sustained or continual improvement in markers of fibrosis and sustained and continual reduction in ELF scores, especially in patients with moderate to advanced disease receiving the 20 mg/kg dose. Patients also experienced stabilization of liver stiffness as measured by transient elastography, especially in those with moderate to advanced disease receiving the 20 mg/kg dose.
Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, commented, 'We believe the nebokitug SPRING trial data are the strongest to date in this debilitating and potentially lethal disease that lacks effective treatment. We are pleased that these positive data were featured at a major multi-disciplinary medical meeting like DDW 2025, as we continue to assess the best options for advancing nebokitug to a Phase 3 trial.'
A copy of the DDW 2025 presentation is now available at the R&D pages of the Chemomab website.
1 CM-101, a novel monoclonal antibody targeting CCL24, was safe, well-tolerated and showed improvements of biomarkers associated with inflammation, fibrosis and cholestasis in patients wit primary sclerosing cholangitis: the SPRING study, CL Bowlus, ST Barclay, D Joshi, MC Londoño, P Mantry, PJ Pockros, R Safadi, R Aricha, C Cirillo, M Frankel, J Lawler, I Vaknin, A Mor, D Thorburn on behalf of the SPRING Study Investigators, DDW 2025, Liver & Biliary Section Distinguished Abstract Plenary, May 4, 2025
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'estimate,' 'intend,' 'may,' 'plan,' 'potentially,' 'will' or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the risk that certain acknowledgements from the End-of-Phase 2 (EOP2) meeting with the FDA in connection with PSC regulatory approval will not materialize into a pathway for regulatory approval; that certain conclusions and assumptions drawn from the EOP2 meeting with the FDA discussed in the press release will prove incorrect and adversely affect the ability for nebokitug to become an FDA fully approved therapy; the risk that the full data set from the nebokitug study or data generated in further clinical trials of nebokitug will not be consistent with the topline results of the nebokitug Phase 2 PSC trial; failure to obtain, or delays in obtaining, regulatory approvals for nebokitug in the U.S., Europe or other territories; failure to successfully commercialize nebokitug, if approved by applicable regulatory authorities, in the U.S., Europe or other territories, or to maintain U.S., European or other territory regulatory approval for nebokitug if approved; uncertainties in the degree of market acceptance of nebokitug by physicians, patients, third-party payors and others in the healthcare community; nebokitug development of unexpected safety or efficacy concerns related to nebokitug; failure to successfully conduct future clinical trials for nebokitug, including due to the Company's potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things; risks that the Company's clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third parties on which the Company is dependent to manufacture sufficient quantities of nebokitug for commercial or clinical needs, to conduct the Company's clinical trials; changes in laws and regulations applicable to the Company's business and failure to comply with such laws and regulations; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; and uncertainties with respect to the Company's need and ability to access future capital; and the intensity and duration of the current war in Israel, and its impact on our operations in Israel. These risks are not exhaustive. You should carefully consider the risks and uncertainties described in the 'Risk Factors' sections of our 20-F for the year ended December 31, 2024. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release. Before you invest, you should read the documents we have filed and will file with the SEC for more complete information about us. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities law of any such state or jurisdiction.
About Chemomab Therapeutics Ltd.Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of nebokitug in patients. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug PSC Phase 3 trial. The design of Phase 3 calls for a single pivotal trial based on a clinical event primary endpoint that provides a clear and streamlined pathway to potential full regulatory approval. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab's nebokitug program for the treatment of systemic sclerosis has an open U.S. IND. For more information, visit: chemomab.com. Contact:
Media and Investors:Barbara LindheimConsulting Vice President, Investor & Public Relations, Strategic CommunicationsPhone: +1 917-355-9234barbara.lindheim@chemomab.comIR@chemomab.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Why Blackberries Are So Good for You, According to Nutrition Experts
Blackberries are gorgeous berries that pop up in grocery stores and farmers' markets just about everywhere in the spring and summertime. While you're likely aware of the health benefits of blueberries and strawberries, you may be less informed about the benefits of blackberries. Here, get the low-down on blackberry nutrition from two dietitians and several recipes to help you usher this superfood into your Zeitlin, a New York City-based registered dietitian and founder of BZ Nutrition Amy Gorin, RDN, a plant-based registered dietitian and owner of Plant Based with AmyRelated: 6 Types of Fruit That Are Loaded With Fiber—Plus, Delicious Ways to Eat More of Them "Blackberries are loaded with vitamin C, which helps to strengthen your immune system and keep your skin looking plump and fresh," says Brigitte Zeitlin, a New York City-based registered dietitian and founder of BZ Nutrition. "They are also high in manganese, which works to keep your bones strong and healthy." Berries, including blackberries, are high in free-radical-fighting antioxidants. Blackberries, in particular, contain anthocyanins, which have antioxidative, antimicrobial, and anti-inflammatory properties. They've been linked to improved vision and brain health. In addition, they offer protection against diseases such as diabetes and cancer due to their ability to protect against free radical damage. Related: 10 Foods That Are Rich in Flavonoids to Reduce Inflammation, Boost Collagen, and More Blackberries are also high in fiber, which helps you feel fuller for longer, says Amy Gorin, RDN, a plant-based registered dietitian and owner of Plant Based with Amy in Stamford, Connecticut. Blackberries' fiber content is also crucial because research has shown that not getting enough fiber can increase your chances of having heart disease. "Eating blackberries may help your LDL, or 'bad,' cholesterol levels," Gorin says. "According to a review study in Scientific Reports, people who regularly ate berries had lower LDL cholesterol levels, versus the people who were not regularly eating berries." Blackberries are also rich in vitamin K, which can help with blood clotting and bone metabolism. Being deficient in vitamin K can lead to heavy menstrual bleeding or make you prone to bruising. If you're on blood thinners, getting enough of this nutrient from blackberries is a great option. Additionally, one study showed that regular blackberry consumption could promote good dental health, and another showed it could help with brain health and prevent memory loss related to aging. While you don't need to be super concerned about overdoing it on blackberries, you may have stomach discomfort if you eat too many due to their higher fiber content. If you have a sensitive stomach, you're likely better off keeping it to a small handful of blackberries per serving. And because they're so dark in color, blackberries may also cause you to see changes in color in your urine if consumed in large amounts, similar to beets. This also isn't cause for concern, so don't feel alarmed if it happens. Related: The 35 Healthiest Foods to Eat Every Day Read the original article on Real Simple
Yahoo
a day ago
- Yahoo
'Reverse SAD' Is A Real Thing. Here Are The Signs.
When you hear the term 'seasonal affective disorder,' odds are you think of wintertime blues. 'We tend to associate shorter days, less sunlight and cold weather with higher chances of depressed mood,' therapist Natalie Moore told HuffPost. 'Conversely, when we think of summertime, we imagine longer days, sunshine and picture people being more joyful and optimistic.' For some people, however, the sunnier seasons bring an emotional struggle. This lesser-known ― and often overlooked ― condition is called 'reverse SAD' or summer-pattern SAD. 'Reverse seasonal affective disorder, or summer-pattern SAD, is a type of depression that occurs during the spring and summer months, as opposed to the more common winter-pattern SAD,' said board-certified psychiatrist and 'Practical Optimism' author Dr. Sue Varma. 'While most people associate SAD with the colder, darker months, some individuals experience a worsening of mood when the days get longer and brighter.' A number of different factors can cause reverse SAD. 'Reverse SAD is thought to affect individuals who are particularly sensitive to circadian rhythm changes,' Moore said. 'Physiological factors include discomfort from increased heat and humidity and sleep disruption caused by early sunrise.' Changes in light exposure can throw off mood-regulating hormones like serotonin and melatonin in the summer, just as in the winter. 'Psychological factors include internal pressure to be happy during this time of year,' Moore said. Summer comes with expectations to be outdoors, attend barbecues, take vacations, and generally be 'on.'Erin Pash, licensed marriage and family therapist The summer can be particularly tough for introverts, since social conventions call for increased participation in potentially energy-depleting activities in the summer. 'Other triggers may include summer stressors like vacation costs, childcare pressures, or problems with body image that are enhanced by our summer wardrobes,' said Dr. Samar McCutcheon, a psychiatrist with The Ohio State University Wexner Medical Center. Summer tends to disrupt routines, which is especially challenging for parents. 'Everything feels a little less structured with kids out of school, parents shuttling children around summer camps, more workload because coworkers are on vacation and pushing off work later at night to accommodate summer day time schedules,' said Mabel Yiu, a marriage and family therapist and founding director of Women's Therapy Institute. 'For people who rely on routine to feel stable, that lack of consistency can be destabilizing.' 'The symptoms of reverse SAD can differ slightly from winter-pattern SAD,' Varma said. 'People should look out for insomnia or trouble sleeping, loss of appetite, difficulty concentrating, irritability or mood swings.' It's common for those with this condition to feel extra pressure, which leads to a challenging disconnect. 'When you're not feeling great but feel like you should be, it can lead to guilt, shame, and isolation, which only worsens mental health,' Yiu said. Although the warm weather months are typically associated with more occasions to socialize, people struggling with reverse SAD may engage in social withdrawal. 'Summer comes with expectations to be outdoors, attend barbecues, take vacations, and generally be 'on,'' said Erin Pash, a licensed marriage and family therapist and founder of Pash Co. 'For someone already struggling, these expectations can feel like a heavy weight.' She recalled a past client who expressed feeling guilty for wanting to stay inside in the air conditioning while it seemed like everyone else was at the beach. They felt as though something was wrong with them for not loving the summertime. 'You might notice you're snappier with family members, avoiding social gatherings you'd normally enjoy or feeling physically uncomfortable even in mildly warm weather,' Pash added. In addition to social withdrawal, restlessness and overwhelm are typical signs of the condition. 'The intense sunlight that energizes others can feel overwhelming, like sensory overload that leaves you agitated rather than refreshed,' Pash said. Many people with reverse SAD report feeling overstimulated and anxious. But ultimately, the biggest sign is timing. Pay attention to patterns in your depression symptoms year over year. 'If you notice that around spring or summer time you experience these signs of reverse SAD, you should speak to your doctor or therapist about your symptoms,' Moore noted. 'Because it's not a well-documented condition, you may need to advocate for yourself in medical environments and seek a mood disorder specialist who has experience treating patients with this issue.' 'Because it is not a well-known mood disorder, the first step in treating and managing reverse SAD is recognizing that you struggle with it,' Moore said. 'Although reverse SAD is rare, you are not alone. Awareness around this condition is increasing.' Take steps to create an environment at home that will support your mental health in the summer. 'Use air conditioning or fans to maintain a comfortable temperature,' Varma advised. 'Heat intolerance is a big trigger. And while bright light can be helpful in the winter, those with reverse SAD may benefit from limiting light during certain times of day, especially in the evening.' Avoid excessive light exposure to promote good sleep as well. 'Use blackout curtains or eye masks if there's still light,' Yiu suggested. 'Minimize blue light screen time and have deliberate dim hours before bed.' Think about lifestyle factors that can affect your mood, and take care of yourself with good nutrition, regular exercise and breaks to rest and recharge. 'Prioritize being proactive about your wellbeing ― nourish your body with healthy food and remember to hydrate and replenish your body,' suggested Rachel Thomasian, a licensed therapist and owner of Playa Vista Counseling. 'Start or maintain a yoga or meditation routine to help manage feelings of anxiety or overwhelm.' Be mindful about your schedule and how you divide your time as well. 'Find indoor activities during the day to avoid being outside at the peak of heat or humidity,' McCutcheon said. 'It can be especially helpful if these activities involve your friends or family, to further prevent depressive symptoms.' She also recommended taking vacations to cooler climates during the summer. 'Give yourself permission to have a different kind of summer,' Pash said. 'Maybe your ideal July evening is a movie night with the AC cranked up, not a rooftop party. That's completely valid. And if you know summer is tough, plan easier months around it. Maybe you schedule your big work projects for fall and keep summer commitments lighter.' The same goes for social commitments. If you find endless summer barbecues too draining, you don't have to say yes to every invitation. 'Let friends and family know that you experience summer differently,' Pash said. 'A simple 'I'm more of a fall person, but I'd love to hang out somewhere air-conditioned' can go a long way.' In addition to leaning on loved ones for support, consider seeking professional help. 'For treatment interventions, cognitive behavioral therapy can be a helpful place to start to treat mild or moderate symptoms, and antidepressants should be considered when someone is experiencing moderate to severe symptoms,' McCutcheon noted. Whatever approach you try, just remember to be kind to yourself. 'Your experience is real and valid, even if it goes against the cultural narrative that summer equals happiness,' Pash said. 'Remember there's no 'right' way to experience any season. Your mental health matters year-round, including during those long, bright summer days.' 13 Vacation Habits That Are Secretly Stressing You Out Is This ADHD Symptom Messing With Your Sex Life? Why Does Talking About Bugs Make You Itchy?
Business Upturn
a day ago
- Business Upturn
Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market
Lupin Limited has announced the launch of its generic version of Ipratropium Bromide Nasal Solution in the United States. The product will be available in both 0.03% and 0.06% strengths and is a therapeutic equivalent to Boehringer Ingelheim's Atrovent® Nasal Spray. This launch marks Lupin's latest addition to its U.S. generic portfolio. The Ipratropium Bromide Nasal Solution 0.03% is used to provide symptomatic relief of rhinorrhea linked to both allergic and nonallergic perennial rhinitis in adults and children aged six and above. The 0.06% version targets rhinorrhea symptoms associated with the common cold or seasonal allergic rhinitis in adults and children aged five and older. According to IQVIA data for the 12 months ending May 2025, the reference drug Atrovent® recorded estimated annual U.S. sales of approximately USD 63 million. With this launch, Lupin aims to tap into the niche respiratory care segment while expanding access to affordable treatment options for patients in the U.S. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
